|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Benefiting from the sensibilization effect and MTX/pMMP-9 co-delivery strategy, this Tf-PAAs-MTX/pMMP-9 co-delivery system exhibited the significantly improved therapeutic efficacy to HNE-1 tumor in a combined manner which was confirmed by <i>in vitro</i> and <i>in vivo</i> assays.
|
31793355 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Benefiting from the sensibilization effect and DOC/pMMP-9 co-delivery strategy, this Tf-HPAA-GO/DOC/pMMP-9 co-delivery system exhibited the significantly improved therapeutic efficacy to HNE-1 tumor in a combined manner which was confirmed by <i>in vitro</i> and <i>in vivo</i> assays.
|
31340676 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Myeloid cells secrete neutrophil elastase and neutrophil extracellular traps (NETs) in response to cues within the tumor microenvironment, thereby leading to enhanced activity in a variety of cancer types.
|
29155217 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor promoting mechanisms of TANs include dampening of CD8<sup>+</sup> response via Arginase-1; a neutrophil-secreted neutrophil elastase (NE) upregulation of tumor cellular proliferation pathways; degradation of basement membrane and ECM via NE and MMP-9; upregulation of angiogenesis by VEGF, and HGF; and ICAM-1 dependent tumor intravasation, immune protection in circulation, and extravasation into distant, metastatic tissue beds.
|
28830617 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A Strong Neutrophil Elastase Proteolytic Fingerprint Marks the Carcinoma Tumor Proteome.
|
27927741 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, the complexes mediated increased DOC concentrations with prolonged blood circulation and EGFP expression in HNE‑1 tumors.
|
29067440 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The findings demonstrated that PML(NLS‑) was detectable in the cytoplasm of NB4‑HA‑NE cells, the tumors in nude mice and in neutrophils from patients with APL.
|
28849126 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lung cancer tumors contain tumor-associated macrophages (TAM) and neutrophils, which release the serine proteases neutrophil elastase (NE) and proteinase 3 (P3) into the tumor microenvironment.
|
28254787 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our results show that NE uptake increases the responsiveness of breast cancer cells to adaptive immunity by broad upregulation of membrane HLA class I and support the conclusion that the innate inflammatory mediator NE enhances tumor cell recognition and increases tumor sensitivity to the host adaptive immune response.
|
27129972 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, we find that MMP-2 and -9, as well as neutrophil elastase (NE), are overexpressed in Tsc2-null myometrial tumors in an estrogen-dependent fashion.
|
26880751 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that NE, which is largely contributed by activated neutrophils in the tumor microenvironment, may be negatively regulating the ability of elafin to arrest cells in G0.
|
25195861 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among the proteolytic enzymes released in the tumor microenvironment we showed that neutrophil elastase cleaved EMILIN1 in three/four major fragments.
|
24513040 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knockdown of α1-antitrypsin by siRNA further enhanced the tumor cell proliferation induced by neutrophil elastase and significantly blocked the anti-proliferation effect of curcumin against neutrophil elastase.
|
22507634 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have recently demonstrated that NE is capable of entering tumor cell endosomes and processing novel intracellular substrates.
|
22915586 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The auto tumor progression mechanism initiated by NE through tumor growth factor-α (TGF-α) was present in breast cancer cells, and this mechanism was intensively suppressed by sivelestat.
|
22213283 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oral administration of EGCG showed similar effects in HLE xenograft tumors.
|
16481065 |
2006 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To define the leukemogenic potential of V72M NE, a tumor watch was established.
|
12384420 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of nine oncogenes (c-myc, N-myc, N-ras, H-ras, k-ras, abl, fos, src, and raf) and two tumor suppressor genes (p53 and RB) were studied by northern blot hybridization in six human hepatocellular carcinoma or hepatoblastoma cell lines (PLC/PRF/5, Hep3B, Hep G2, 2.2.15, HLE, and HLF) and in a human embryonic lung fibroblast cell line (WI-38) to look for differences that might be associated with the presence (PLC/PRF/5, Hep3B, and 2.2.15) or absence (Hep G2, HLE, and HLF) of integrated hepatitis B virus (HBV) DNA.
|
1335479 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumorigenicity of the HNE-1 and HONE-1 cells was demonstrated by tumor induction in nude mice.
|
2153642 |
1990 |